A Phase 3, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety of Tramadol Infusion (AVE-901) in the Management of Post-Operative Pain Following Surgery

Trial Profile

A Phase 3, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety of Tramadol Infusion (AVE-901) in the Management of Post-Operative Pain Following Surgery

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Tramadol (Primary)
  • Indications Postoperative pain
  • Focus Adverse reactions; Registrational
  • Sponsors Avenue Therapeutics
  • Most Recent Events

    • 02 Jan 2018 According to an Avenue Therapeutics media release, the first patients have been dosed in this trial. The results of this trial will support a new drug application (NDA), which the company expects to submit to the US FDA in late 2019.
    • 02 Jan 2018 Status changed from planning to recruiting according to an Avenue Therapeutics media release.
    • 20 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top